Palatin Technologies (PTN) Change in Accured Expenses (2010 - 2026)
Palatin Technologies' (PTN) quarterly Change in Accured Expenses came in at -$6444.0 in Q1 2026, up 99.44% YoY from -$3231.1 in Q1 2025, and up 67.98% on a QoQ basis from -$20124.0 in Q4 2025.
Palatin Technologies (PTN) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 17 years of Change in Accured Expenses data on file, last reported at -$6444.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 99.44% year-over-year to -$6444.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $146937.0 (up 103.74% YoY) and the FY2025 annual result came in at -$3.3 million, down 39.53% from the prior year.
- Change in Accured Expenses grew to -$6444.0 in Q1 2026, from -$20124.0 in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $641212.0 in Q3 2023 to a low of -$2.9 million in Q4 2024.
- A 5-year average of -$582939.9 and a median of -$389271.0 in 2023 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses plunged 3140.71% — and 2025, when it jumped 250.73%.
- Tracing PTN's Change in Accured Expenses over 5 years: stood at -$51020.0 in 2022, then sank by 3140.71% to -$1.7 million in 2023, then tumbled by 76.76% to -$2.9 million in 2024, then soared by 99.31% to -$20124.0 in 2025, then jumped by 67.98% to -$6444.0 in 2026.
- The last three Change in Accured Expenses figures came in at -$6444.0 (Q1 2026), -$20124.0 (Q4 2025), and -$201447.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - | -6,444.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6,444.00 |
| Mar 31, 2026 | -6,444.00 |
| Dec 31, 2025 | -20,124.00 |
| Dec 31, 2025 | -20,124.00 |
| Sep 30, 2025 | -201,447.00 |
| Sep 30, 2025 | -201,447.00 |
| Jun 30, 2025 | 374,952.00 |
| Jun 30, 2025 | 374,952.00 |
| Mar 31, 2025 | -1.14 Mn |
| Mar 31, 2025 | -1.14 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Dec 31, 2024 | -2.92 Mn |
| Sep 30, 2024 | 388,246.00 |
| Sep 30, 2024 | 388,246.00 |
| Jun 30, 2024 | -248,754.00 |
| Jun 30, 2024 | -248,754.00 |
| Mar 31, 2024 | -1.11 Mn |
| Mar 31, 2024 | -1.11 Mn |
| Dec 31, 2023 | -1.65 Mn |
| Dec 31, 2023 | -1.65 Mn |